{"id":4304,"date":"2017-08-12T11:10:18","date_gmt":"2017-08-12T11:10:18","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/2017\/08\/12\/clinical-and-translational-oncology-feasibility-of-a-deep-hyperthermia-and-radiotherapy-programme-for-advanced-tumors-first-spanish-experience\/"},"modified":"2025-09-04T13:39:26","modified_gmt":"2025-09-04T13:39:26","slug":"klinik-calisma-hipertermi-karsinom","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/tr\/klinik-calisma-hipertermi-karsinom\/","title":{"rendered":"Klinik \u00e7al\u0131\u015fma: Lokal olarak ilerlemi\u015f serviks karsinomu i\u00e7in kemoradyoterapi art\u0131 hipertermi ve y\u00fcksek doz brakiterapinin \u00f6n sonu\u00e7lar\u0131"},"content":{"rendered":"
<\/div>\n
\n

Klinik \u00e7al\u0131\u015fma: Lokal olarak ilerlemi\u015f serviks karsinomu i\u00e7in kemoradyoterapi art\u0131 hipertermi ve y\u00fcksek doz brakiterapinin \u00f6n sonu\u00e7lar\u0131<\/span><\/span><\/a><\/h1>\n

Andromedic hipertermi klinik \u00e7al\u0131\u015fmas\u0131 – Avrupa Hipertermik Onkoloji Derne\u011fi kongresi 2014\u00a0<\/span><\/span><\/a><\/h2>\n

<\/h2>\n
\"Klinik
Lokal ileri evre serviks karsinomu i\u00e7in kemoradyoterapi art\u0131 Andromedic hipertermi ve y\u00fcksek doz brakiterapinin \u00f6n sonu\u00e7lar\u0131<\/span><\/span><\/figcaption><\/figure>\n

E. Clarke, V. De Sanctis, C. Scaringi, M. Valeriani, MF Osti, R. Maurizi Enrici Sant’Andrea Hastanesi, Radyoterapi B\u00f6l\u00fcm\u00fc, Roma ‘Sapienza” \u00dcniversitesi, Roma. \u0130talya<\/span><\/span><\/p>\n

AMA\u00c7LAR:<\/span><\/span><\/strong> Lokal ileri evre serviks karsinomu (LACC) i\u00e7in kemoradyoterapi art\u0131 hipertermi (HT) ve y\u00fcksek doz brakiterapinin (BRT) sonu\u00e7lar\u0131n\u0131 ara\u015ft\u0131rmak. Kemoradyoterapinin LACC’de standart tedavi olarak kabul edilip edilmedi\u011fi ara\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r. HT’nin radyoterapiye (RT) tek ba\u015f\u0131na eklenmesinin, bu hasta grubunda tedaviye ba\u011fl\u0131 3. ila 4. evre akut veya ge\u00e7 toksisiteyi etkilemeden lokal t\u00fcm\u00f6r kontrol\u00fcn\u00fc ve genel sa\u011fkal\u0131m\u0131 iyile\u015ftirdi\u011fi g\u00f6sterilmi\u015ftir.<\/span><\/span><\/p>\n

GERE\u00c7 VE Y\u00d6NTEMLER<\/span><\/span><\/strong> Ocak 2013 ile Aral\u0131k 2013 tarihleri \u200b\u200baras\u0131nda histerektomi sonras\u0131 LACC veya lokal tekrarlayan serviks karsinomu (LRCC) olan 8 hasta (s\u0131ras\u0131yla 3 evre IIB. I IIIB. 2 NEI ve 3 LRCC) haftal\u0131k sisplatin ve HT ile yo\u011funluk mod\u00fclasyonlu radyoterapiyi (IMRT) ve ard\u0131ndan BRT’yi birle\u015ftiren bir pilot \u00e7al\u0131\u015fmaya kaydedildi. Pelvik lenf nodlar\u0131na 50,4 Gy’lik bir doz ve br\u00fct t\u00fcm\u00f6r hacmine (GTV) e\u015f zamanl\u0131 entegre boost (SIB) ile toplam 61,8 Gy’lik bir doz 28 fraksiyonda 5,5 hafta i\u00e7inde uyguland\u0131. BRT dozu 3 fraksiyonda 21 Gy idi. E\u015f zamanl\u0131 kemoterapi rejimi haftal\u0131k sisplatin 4\/mg\/m2 ve HT haftada bir kez uyguland\u0131.<\/span><\/span><\/p>\n

BULGULAR T\u00fcm hastalarda lokal kontrol sa\u011fland\u0131. Bir hastada pelvis d\u0131\u015f\u0131nda \u00e7oklu kemik ve paraaortik nod\u00fcl tutulumu ile n\u00fcks g\u00f6r\u00fcld\u00fc. Tedaviye ba\u011fl\u0131 akut veya ge\u00e7 evre 3-4 toksisite g\u00f6zlenmedi.<\/span><\/span><\/strong><\/p>\n

SONU\u00c7LAR Bu tedavi rejimi iyi tolere edilmi\u015f ve iyi bir klinik yan\u0131t vermi\u015ftir. Kemoradyoterapiye HT eklenmesi, umut vadeden yeni bir stratejidir.<\/span><\/span><\/strong> Etkinli\u011fini do\u011frulamak i\u00e7in \u00e7ok kurumlu i\u015f birli\u011fi \u00e7al\u0131\u015fmalar\u0131 ve daha uzun takiplere ihtiya\u00e7 vard\u0131r.<\/span><\/span><\/p>\n

KAYNAK\u00c7A<\/span><\/span><\/p>\n

1. Lutgens L. van der Zee J. Pijls-Johannesma M, De Haas-Kock DF, Buijsen J. Mastrigt GA. Lammering G. De Ruysscher DK. Lambin R. Lokal olarak ilerlemi\u015f serviks karsinomunun tedavisinde hipertermi ve radyasyon tedavisinin birlikte kullan\u0131m\u0131. Cochrane Veritaban\u0131 Syst Rev. 2010 Mart 17:(3):CD008377. doi:10.1002\/14851858.CD006377.pub3.<\/span><\/span><\/p>\n

2. van der Zee J. Gonzalez Gonzalez D. van Rhoon GC, van Dijk JD. van Pullen WL, Hart AA. Lokal olarak ilerlemi\u015f pelvik t\u00fcm\u00f6rlerde radyoterapi ile hipertermi kombinasyonunun tek ba\u015f\u0131na radyoterapi ile kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131: prospektif, randomize, mulbcentre \u00e7al\u0131\u015fmas\u0131. Dutch Deep Hyperthemba Group. Lancet. 2000 Nisan 1:355(9210):1119-25.<\/span><\/span><\/p>\n

3. Green J, Kirwan .1, Tremey J. Vale C. Symonds R Fresco L. Williams C. Collingwood M. Rahim a\u011fz\u0131 kanserinde e\u015f zamanl\u0131 kemoterapi ve radyasyon tedavisi. Cochrane Veritaban\u0131 Sistemi Rev. 20 Temmuz 2005;(3):C0002225.<\/span><\/span><\/p>\n

 <\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Klinik \u00e7al\u0131\u015fma: Lokal olarak ilerlemi\u015f serviks karsinomu i\u00e7in kemoradyoterapi art\u0131 hipertermi ve y\u00fcksek doz brakiterapinin \u00f6n sonu\u00e7lar\u0131 Andromedic hipertermi klinik \u00e7al\u0131\u015fmas\u0131 – Avrupa Hipertermik Onkoloji Derne\u011fi kongresi 2014\u00a0 E. Clarke, V. De Sanctis, C. Scaringi, M. Valeriani, MF Osti, R. Maurizi Enrici Sant’Andrea Hastanesi, Radyoterapi B\u00f6l\u00fcm\u00fc, Roma ‘Sapienza” \u00dcniversitesi, Roma. \u0130talya AMA\u00c7LAR: Lokal ileri evre…<\/p>\n","protected":false},"author":1,"featured_media":7032,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[197],"tags":[227,228,229,230,231],"class_list":["post-4304","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-tr","tag-advanced-tumors-tr","tag-hyperthermia-tr","tag-local-hyperthermia-tr","tag-meht-tr","tag-radiotherapy-tr"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts\/4304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/comments?post=4304"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts\/4304\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/media\/7032"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/media?parent=4304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/categories?post=4304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/tags?post=4304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}